As Movember is here, it’s time to spotlight men's health. Join us in this mission by spreading awareness and encouraging the use of advanced diagnostic tools! We are proud to support testicular cancer diagnostics with the M371-Test, a game-changer qPCR-based assay.
Testicular cancer is the world’s most common cancer among young men, aged 15-39. Early detection and reliable diagnosis are key elements to provide the best treatment for this highly curable cancer. The M371-Test serves as an aid for primary diagnosis and follow-up monitoring of testicular germ cell tumors (TGCT). It measures the relative quantity of the tumor marker miR-371a-3p from a blood sample with outstanding diagnostic accuracy.
What makes the M371-Test stand out?
Explore the scientific publications supporting the M371-Test's efficacy:
If you are interested in learning more about this test, visit the M371-Test product page and contact us.
The assay is manufactured by mir|detect and distributed by Gold Standard Diagnostics Frankfurt GmbH.
Connect with us, raise awareness, and let's make a lasting impact together!